You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company said the COVID-19 pandemic and resulting stay-at-home orders have led to a slowdown in testing service volumes in recent weeks.
Starting late March and into its fiscal fourth quarter, social distancing guidelines began significantly impacting test volume trends, the company said.
Approximately 80 percent of gross product placements in the quarter were associated with interest in COVID-19 testing, the firm said
The company said that its preliminary revenues are expected to be down almost 8 percent year over year due to the pandemic.
The company said that as the COVID-19 pandemic spread throughout the world, it saw a "significant reduction in customer activity" by late March.
The GenomeWeb Index fared better than its benchmark counterparts in March, but still fell more than 4 percent.
The company said Q4 revenue growth was driven by an increase in testing volume and analytical services provided to the US Department of Veterans Affairs.
The company said its sales team will serve healthcare providers by telephone and online until it's safe to return to the field.
The skin cancer diagnostics company said it delivered 37 percent more DecisionDx-Melanoma test results in Q4 2019 than in the previous year's fourth quarter.
More than 70 percent of ePlex analyzer placements in the fourth quarter were within labs that previously had a competitive analyzer, the firm said.
Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.
The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.
In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.
According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.